Peyman Kabolizadeh

Peyman Kabolizadeh practices at Memorialcare Radiation Oncology - HOPD in Laguna Hills, California.

Peyman Kabolizadeh's NPI, 1093941171, was assigned on June 3, 2009. Peyman Kabolizadeh graduated from VCU School of Medicine in 2009. Peyman Kabolizadeh holds Michigan license 4301107331.

Peyman Kabolizadeh's primary practice is Memorialcare Radiation Oncology - HOPD, at 24302 Paseo De Valencia, Laguna Hills, CA 92653.

Peyman Kabolizadeh's primary practice is Memorialcare Radiation Oncology - HOPD in Laguna Hills, California. Peyman Kabolizadeh is also affiliated with UCI Health - Orange. The medical group on file is Memorial Radiation Oncology Medical Group. Dmand AI also links Peyman Kabolizadeh to 2 more hospitals and 1 group practice or clinic, each named with a free account. Peyman Kabolizadeh's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Peyman Kabolizadeh practices, 5 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Peyman Kabolizadeh's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Peyman Kabolizadeh is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Peyman Kabolizadeh's licenses on file in 5 states: Michigan, California, Massachusetts, Pennsylvania and Virginia.

Dmand AI lists anal cancer radiation, bone cancer radiation, brain cancer radiation, brain tumor radiation, breast cancer radiation, cancer radiation-upper GI, colorectal cancer radiation and head & neck cancer radiation among the conditions Peyman Kabolizadeh treats.

CMS data shows 2,826 Medicare services from Peyman Kabolizadeh across 20 procedure codes in 2024, for 389 Medicare patients. Medicare paid $214,549 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 389 Medicare patients who saw Peyman Kabolizadeh in 2024. The largest group is 65 to 74, with 220 patients. 75% of them have cancer, and 75% have high blood pressure. 27% are also on Medicaid. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Peyman Kabolizadeh's median patient age at 69, with 65% women.

In 2024, Peyman Kabolizadeh wrote 66 Medicare Part D claims for 50 patients. 71% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $79 in total drug cost. In 2023, CMS named 44 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 85 out of 100 for Peyman Kabolizadeh for performance year 2024, reported as part of a group. Peyman Kabolizadeh accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 37 papers to Peyman Kabolizadeh, published from 2007 to 2023. 2021 was the busiest year, with 5. The most frequent topics are Proton Therapy, Radiotherapy Dosage and Radiotherapy, Intensity-Modulated. Peyman Kabolizadeh has published most often in Radiat Oncol. Peyman Kabolizadeh's most frequent co-authors are Craig W. Stevens, MD, Dwight Earl Heron, MD and Di Yan, MD.

CMS Open Payments shows 77 general payments to Peyman Kabolizadeh from 19 drug and device companies from 2016 to 2025. Honoraria make up the largest share, 48% of the total. Ion Beam Applications S.A. paid the most, $13,197.

Peyman Kabolizadeh graduated from VCU School of Medicine in 2009.

Peyman Kabolizadeh is in network with 17 carriers, including Elevance, Health Alliance Plan and Aetna. Medicare plans come from the most carriers, 11. Check the plan with the practice before a visit.